TABLE 3.
Data for baseline and longitudinal visits
| Severe nonsmoking asthma (n = 205) | Smokers and ex‐smokers with severe asthma (n = 58) | SNA | SSA | |||
|---|---|---|---|---|---|---|
| Baseline | Longitudinal | Baseline | Longitudinal | p‐Value | pValue | |
| Longitudinal visit subjects with pulmonary test, n | 205 | 204 | 58 | 58 | ||
| pre‐BD FVC, L (Mean (SD)) | 2.61 (0.75) | 2.64 (0.74) | 3.04 (0.70) | 3.15 (0.76) | 0.640 | 0.501 |
| pre‐BD FEV1, L (Mean (SD)) | 1.56 (0.56) | 1.61 (0.54) | 1.71 (0.60) | 1.81 (0.72) | 0.208 | 0.545 |
| pre‐BD FEV1% predicted (Mean (SD)) | 65.62 (21.54) | 68.85 (21.09) | 58.38 (18.89) | 62.21 (22.39) | 0.093 | 0.436 |
| pre‐BD FEV1/FVC, %(Mean(SD)) | 59.50 (12.34) | 60.92 (12.20) | 55.74 (12.30) | 56.23 (13.13) | 0.222 | 0.804 |
| Longitudinal visit subjects with bronchodilator reversibility test, n | 190 | 190 | 56 | 56 | ||
| FEV1 reversibility (L), median(IQR) | 0.28 (0.22, 0.38) | 0.18 (0.09, 0.27) | 0.27 (0.18, 0.42) | 0.23 (0.16, 0.37) | <.001 | 0.322 |
| FEV1 reversibility (%), median (IQR) | 20.74 (13.66, 31.11) | 12.12(5.91, 20.75) | 15.98 (8.78, 31.10) | 14.90 (8.31, 22.28) | <.001 | 0.480 |
| Healthcare resource utilization,n(%) | 205 | 205 | 58 | 58 | ||
| Yes | 43 (21.0) | 64 (31.2) | 7 (12.1) | 16 (27.6) | 0.024 | 0.061 |
| No | 162 (79.0) | 141 (68.8) | 51 (87.9) | 42 (72.4) | ||
| Subjects with questionnaire, n | 205 | 205 | 57 | 57 | ||
| ACQ | ||||||
| ACQ5 | 1.65 (1.03) | 1 | 1.81 (0.98) | 1.56 (1.07) | 0.012 | 0.158 |
| ACQ7 | 1.85 (0.86) | 1.65 (0.82) | 2.08 (0.85) | 1.84 (0.94) | 0.017 | 0.121 |
| AQLQ | ||||||
| AQLQ | 4.54 (1.02) | 4.83 (1.07) | 4.71 (1.06) | 4.91 (1.02) | 0.005 | 0.296 |
| Symptoms | 4.76 (1.07) | 5.06 (1.06) | 4.78 (1.06) | 5.09 (1.01) | 0.004 | 0.129 |
| Activity limitation | 4.46 (1.02) | 4.76 (1.09) | 4.67 (1.21) | 4.87 (1.16) | 0.004 | 0.392 |
| Emotional | 4.44 (1.37) | 4.75 (1.35) | 4.69 (1.33) | 4.79 (1.48) | 0.018 | 0.716 |
| Environmental | 4.19 (1.46) | 4.40 (1.50) | 4.60 (1.46) | 4.62 (1.50) | 0.106 | 0.925 |
| ESS | 6.87 (4.2) | 6.66 (4.4) | 7.46 (4.42) | 7.58 (4.73) | 0.393 | 0.889 |
| MARS | 21.44 (2.92) | 21.45 (3.33) | 21.77 (2.8) | 21.84 (2.69) | 0.599 | 0.961 |
| Subjects with FeNO, n | 192 | 194 | 54 | 54 | ||
| FeNO(ppb) | 29.50 [20.00, 52.00] | 28.00 [18.25, 48.00] | 26.50 [18.00, 63.50] | 29.00 [16.25,48.50] | 0.758 | 0.775 |
| Subjects with blood results, n | 205 | 197 | 58 | 57 | ||
| Neutrophil count(10∧9/L) | 3.60 [3.00, 4.50] | 3.54 [2.85, 4.59] | 3.90 [3.27,4.95] | 3.89 [2.90,5.21] | 0.580 | 0.775 |
| Eosinophil count(10∧9/L) | 0.23 [0.11, 0.40] | 0.23 [0.11, 0.44] | 0.26 [0.13,0.40] | 0.20 [0.12,0.42] | 0.501 | 0.745 |
| Neutrophil (%) | 57.70 [52.20, 64.20] | 58.90 [52.30, 64.70] | 60.85 [52.85, 66.68] | 59.10 [50.40, 67.00] | 0.703 | 0.576 |
| Eosinophil (%) | 3.60 [1.90, 6.50] | 4.20 [1.90, 7.00] | 3.60 [2.18, 6.37] | 3.30 [1.80, 6.00] | 0.320 | 0.724 |
| Subjects with IgE and ECP results, n | 169 | 162 | 47 | 50 | ||
| ECP (μg/L) | 7.77 [4.03, 16.20] | 7.05 [4.10, 13.73] | 6.98 [4.55, 14.95] | 6.99 [4.30, 14.95] | 0.389 | 0.745 |
| IgE Total (Ku/L) | 165.00 [57.80, 407.00] | 168.50 [62.98, 378.75] | 320.00 [128.50, 909.00] | 321.00 [94.57, 1189.00] | 0.760 | 0.940 |
| Atopy* | ||||||
| above normal | 88 (52.07) | 89 (54.94) | 29 (61.70) | 24 (48.00) | 0.659 | 0.222 |
| normal | 81 (47.93) | 73 (45.06) | 18 (38.30) | 26 (52.00) | ||
Data are presented as mean (standard deviation) or median (interquartile range) for continuous variables, n (%) for categorical variables.
Note: Using all severe patients without missing value.
Abbreviations: FEV1, forced expiratory volume in one second; FVC, forced vital capacity; BD. bronchodilator.
Note: P‐values are based on the comparison between baseline and longitudinal values. The Kruskal‐Wallis test was used for continuous data and the Fisher exact test for discrete data.
*
Atopy (above normal) means the subjects have at least one above normal (>0.35) records for HX2, FX5, MX2, TX4, WX5, and Phadiatop.